The DP receptor, allergic inflammation and asthma

被引:60
作者
Kabashima, K [1 ]
Narumiya, S [1 ]
机构
[1] Kyoto Univ, Fac Med, Dept Pharmacol 2, Sakyo Ku, Kyoto 6068501, Japan
来源
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS | 2003年 / 69卷 / 2-3期
关键词
prostaglandin D-2; DP; allergy; inflammation; asthma; conjunctivitis; colitis; skin; pain; sleep;
D O I
10.1016/S0952-3278(03)00080-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostaglandin (PG) D-2 is the major cyclooxygenase metabolite of arachidonic acid produced by mast cells in response to allergen in diseases, such as asthma, atopic dermatitis, allergic rhinitis and allergic conjunctivitis. However, whether PGD(2) regulates allergic process per se, and, if so, whether it facilitates or down-regulates the disease process has remained unknown. PGD(2) exerts its actions by binding to two types of specific cell surface receptor. One is DP (the PGD receptor) and the other is chemoattractant receptor-homologous molecule expressed on Th2. Between the two, the DP receptor has been better characterized since its cDNA cloning in 1994, and novel class of DP antagonists have been and are being developed. Furthermore, mice deficient in DP were generated and have been subjected to several models of allergic diseases to reveal the role of PGD(2) in allergy. In this article, we summarize these findings and provide an overview of the current status of the DP receptor research to discuss the therapeutic potential of modulating the PGD(2)-DP pathway in allergic diseases. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:187 / 194
页数:8
相关论文
共 58 条
[21]   EFFECTS OF INTRAVENOUS INFUSIONS OF PROSTAGLANDIN-D2 IN MAN [J].
HEAVEY, DJ ;
LUMLEY, P ;
BARROW, SE ;
MURPHY, MB ;
HUMPHREY, PPA ;
DOLLERY, CT .
PROSTAGLANDINS, 1984, 28 (06) :755-767
[22]   Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2 [J].
Hirai, H ;
Tanaka, K ;
Yoshie, O ;
Ogawa, K ;
Kenmotsu, K ;
Takamori, Y ;
Ichimasa, M ;
Sugamura, K ;
Nakamura, M ;
Takano, S ;
Nagata, K .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (02) :255-261
[23]   MOLECULAR CHARACTERIZATION OF A MOUSE PROSTAGLANDIN-D RECEPTOR AND FUNCTIONAL EXPRESSION OF THE CLONED GENE [J].
HIRATA, M ;
KAKIZUKA, A ;
AIZAWA, M ;
USHIKUBI, F ;
NARUMIYA, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (23) :11192-11196
[24]  
Holgate ST, 1998, CLIN EXP ALLERGY, V28, P97
[25]   PROSTAGLANDIN-D2 - A BIOCHEMICAL PERSPECTIVE [J].
ITO, S ;
NARUMIYA, S ;
HAYAISHI, O .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 1989, 37 (04) :219-234
[26]   THE EFFECTS OF AN ORAL THROMBOXANE TP RECEPTOR ANTAGONIST BAY U-3405, ON PROSTAGLANDIN D2-INDUCED AND HISTAMINE-INDUCED BRONCHOCONSTRICTION IN ASTHMA, AND RELATIONSHIP TO PLASMA DRUG CONCENTRATIONS [J].
JOHNSTON, SL ;
BARDIN, PG ;
HARRISON, J ;
RITTER, W ;
JOUBERT, JR ;
HOLGATE, ST .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (05) :402-408
[27]   The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut [J].
Kabashima, K ;
Saji, T ;
Murata, T ;
Nagamachi, M ;
Matsuoka, T ;
Segi, E ;
Tsuboi, K ;
Sugimoto, Y ;
Kobayashi, T ;
Miyachi, Y ;
Ichikawa, A ;
Narumiya, S .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (07) :883-893
[28]   NONSTEROIDAL ANTIINFLAMMATORY DRUGS ACTIVATE QUIESCENT INFLAMMATORY BOWEL-DISEASE [J].
KAUFMANN, HJ ;
TAUBIN, HL .
ANNALS OF INTERNAL MEDICINE, 1987, 107 (04) :513-516
[29]   AH6809, A PROSTAGLANDIN DP-RECEPTOR BLOCKING DRUG ON HUMAN-PLATELETS [J].
KEERY, RJ ;
LUMLEY, P .
BRITISH JOURNAL OF PHARMACOLOGY, 1988, 94 (03) :745-754
[30]   Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells [J].
Kiriyama, M ;
Ushikubi, F ;
Kobayashi, T ;
Hirata, M ;
Sugimoto, Y ;
Narumiya, S .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 122 (02) :217-224